The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Sarcosine or D-Serine Add-on Treatment for Acute Exacerbation of Schizophrenia: A Randomized, Double-blind, Placebo-Controlled Study
Abstract
CONTEXT: Agents that enhance N-methyl-D-aspartate (NMDA) function through the glycine modulatory site (D-serine, glycine, or D-cycloserine) or through glycine transporter 1 (sarcosine) improve the symptoms of patients with stable chronic schizophrenia. OBJECTIVE: To determine whether NMDA-glycine site agonists or glycine transporter-1 inhibitors have better efficacy and whether NMDA receptor-enhancing agents have beneficial effects for acute exacerbation of schizophrenia. DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: Inpatient units of 2 major medical centers in Taiwan. Patients Sixty-five schizophrenic inpatients with acute exacerbation. INTERVENTIONS: Six weeks of treatment with sarcosine (2 g/d), D-serine (2 g/d), or placebo and concomitant optimal risperidone therapy. MAIN OUTCOME MEASURES: Positive and Negative Syndrome Scale (PANSS) and Scale for the Assessment of Negative Symptoms (SANS) (20 and 17 items) total scores. RESULTS: The sarcosine group revealed more reductions in PANSS total scores than the placebo (P = .04) and D-serine (P<.001) groups. Sarcosine adjunctive treatment was also superior to placebo in reducing SANS-20 (P = .007) and SANS-17 (P = .003) scores and to D-serine in decreasing SANS-20 (P = .006) and SANS-17 (P = .002) scores. The PANSS-general, PANSS-cognitive, and PANSS-depressive symptoms scores and SANS-alogia and SANS-blunted affect scores improved significantly more in sarcosine-cotreated patients than in risperidone monotherapy patients (P< or =.02 for all). Sarcosine adjunctive therapy also surpassed D-serine in terms of PANSS-general, PANSS-positive, PANSS-negative, and PANSS-depressive symptoms scores (P< or =.04 for all). D-serine and risperidone cotreatment did not differ significantly from risperidone monotherapy in all efficacy domains. CONCLUSIONS: This first short-term treatment study on NMDA receptor-enhancing agents suggests that sarcosine, superior to D-serine, can benefit not only patients with long-term stable disease but also acutely ill persons with schizophrenia. This finding indicates that a glycine transporter 1 inhibitor may be more efficacious than NMDA-glycine site agonists for adjuvant treatment of schizophrenia, at least during the acute phase. Further studies are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
(1976) · Medical Entomology and Zoology · Cited by 8,899
Models for Longitudinal Data: A Generalized Estimating Equation Approach
Zeger, S. L., Liang, K.-Y., & Albert, P. S. (1988) · Biometrics · doi:10.2307/2531734 · Cited by 4,505
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705
D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia
Tsai, G. E., Yang, P., Chang, Y.-C., & Chong, M.-Y. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.032 · Cited by 674
Self-citationSchizophrenia: Diverse Approaches to a Complex Disease
Sawa, A., & Snyder, S. H. (2002) · Science · doi:10.1126/science.1070532 · Cited by 597
The Glutamatergic Dysfunction Hypothesis for Schizophrenia
Coyle, J. T. (1996) · Harvard Review of Psychiatry · doi:10.3109/10673229609017192 · Cited by 568 · cited 1×
“The NMDA neurotransmission regulates synaptic plasticity, memory, and cognition.(43) This cognitionenhancing effect is also supported by the positive findings of a D-serine study,(4) which applied the Wisconsin Card Sorting Test.”
ResultEfficacy of High-Dose Glycine in the Treatment of Enduring Negative Symptoms of Schizophrenia
Heresco-Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Silipo, G., & Lichtenstein, M. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.29 · Cited by 487
Goff, D. C., Tsai, G., Levitt, J., Amico, E., Manoach, D., Schoenfeld, D. A., Hayden, D. L., McCarley, R., & Coyle, J. T. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.21 · Cited by 436
Self-citationCloning and expression of a glycine transporter reveal colocalization with NMDA receptors
Smith, K. E., Borden, L. A., Hartig, P. R., Branchek, T., & Weinshank, R. L. (1992) · Neuron · doi:10.1016/0896-6273(92)90207-t · Cited by 423
Modulation of N -methyl- d -aspartate receptor function by glycine transport
Bergeron, R., Meyer, T. M., Coyle, J. T., & Greene, R. W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15730 · Cited by 411
Tsai, G., Lane, H.-Y., Yang, P., Chong, M.-Y., & Lange, N. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.09.012 · Cited by 342
Self-citationGomeza, J., Hülsmann, S., Ohno, K., Eulenburg, V., Szöke, K., Richter, D., & Betz, H. (2003) · Neuron · doi:10.1016/s0896-6273(03)00672-x · Cited by 294
A “Glutamatergic Hypothesis” of Schizophrenia: Rationale for Pharmacotherapy with Glycine
Deutsch, S. I., Mastropaolo, J., Schwartz, B. L., Rosse, R. B., & Morihisa, J. M. (1989) · Clinical Neuropharmacology · doi:10.1097/00002826-198902000-00001 · Cited by 268
Five-Factor Model of Schizophrenia Initial Validation
LINDENMAYER, J.-P., BERNSTEIN-HYMAN, R., & GROCHOWSKI, S. (1994) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199411000-00006 · Cited by 258
Heresco-Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Horowitz, A., & Kelly, D. (1996) · British Journal of Psychiatry · doi:10.1192/bjp.169.5.610 · Cited by 255
Chen, L., Muhlhauser, M., & Yang, C. R. (2003) · Journal of Neurophysiology · doi:10.1152/jn.00680.2002 · Cited by 230
High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia
Heresco-Levy, U., Ermilov, M., Lichtenberg, P., Bar, G., & Javitt, D. C. (2004) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00707-8 · Cited by 222
Assessing Normality in Random Effects Models
Lange, N., & Ryan, L. (1989) · The Annals of Statistics · doi:10.1214/aos/1176347130 · Cited by 203
Høyberg, O. J., Fensbo, C., Lingjærde, O., Sloth‐Nielsen, M., Salvesen, I., & Remvig, J. (1993) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1993.tb03480.x · Cited by 176
Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia
Peuskens, J., Bech, P., Möller, H.-J., Bale, R., Fleurot, O., & Rein, W. (1999) · Psychiatry Research · doi:10.1016/s0165-1781(99)00075-x · Cited by 170
Heresco-Levy, U., Ermilov, M., Shimoni, J., Shapira, B., Silipo, G., & Javitt, D. C. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.480 · Cited by 167
McBain, C. J., Kleckner, N. W., Wyrick, S., & Dingledine, R. (1989) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09633-6 · Cited by 164
Heresco‐Levy, U., & Javitt, D. C. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)00129-4 · Cited by 121
Blin, O., Azorin, J. M., & Bouhours, P. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199602000-00007 · Cited by 117
Javitt, D. C., Balla, A., Burch, S., Suckow, R. F., Xie, S., & Sershen, H. W. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300313 · Cited by 104
Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors
Javitt, D. C., Balla, A., Sershen, H. W., & Lajtha, Á. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00237-6 · Cited by 99
HUTTUNEN, M. O., Piepponen, P. T., Rantanen, H., Larmo, I., Nyholm, R., & Raitasuo, V. (1995) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1995.tb09781.x · Cited by 95
Herdon, H. J., GODFREY, F., Brown, A. M., Coulton, S., Evans, J. R., & Cairns, W. J. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00043-0 · Cited by 91
Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia
Tsai, G. E., van Kammen, D. P., Chen, S., Kelley, M. E., Grier, A., & Coyle, J. T. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00151-6 · Cited by 80
Self-citationRisperidone in Acutely Exacerbated Schizophrenia
Lane, H., Chiu, W., Chou, J. C. Y., Wu, S.-T., Su, M., & Chang, W. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0311 · Cited by 65
Self-citationAre Tryptophan and 5-Hydroxytryptophan Effective Treatments for Depression? A Meta-Analysis
Shaw, K. A.-M., Turner, J., & Mar, C. D. (2002) · Australian & New Zealand Journal of Psychiatry · doi:10.1046/j.1440-1614.2002.01046.x · Cited by 59
Heresco‐Levy, U., Silipo, G. S., & Javitt, D. (1996) · PubMed · Cited by 53
Zhang, X.-Y., Zhou, D. F., Cao, L., Zhang, P.-Y., Wu, G. Y., & Shen, Y. (2001) · International Clinical Psychopharmacology · doi:10.1097/00004850-200111000-00002 · Cited by 50
Symptoms at index admission as predictor for 1‐5 year outcome in schizophrenia
Wieselgren, I., Lindström, E., & Lindström, L. (1996) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1996.tb09866.x · Cited by 47
sar: a genetic mouse model for human sarcosinemia generated by ethylnitrosourea mutagenesis.
Harding, C. O., Williams, P. J., Pflanzer, D. M., Colwell, R. E., Lyne, P., & Wolff, J. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2644 · Cited by 21
Fine-tuning risperidone dosage for acutely exacerbated schizophrenia: clinical determinants
Lane, H., Chang, Y., Chiu, C., Lee, S.-H., Lin, C.-Y., & Chang, W. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1685-6 · Cited by 17
Self-citation
Cited by
Glutamate receptor ion channels
Mayer, M. L. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.05.004 · Cited by 3,640
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568
Moghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917
“Furthermore, sarcosine appeared to be more effective in the acutely symptomatic patients (Lane et al., 2005).”
BackgroundRoss, C. A., Margolis, R. L., Reading, S. A. J., Pletnikov, M., & Coyle, J. T. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.015 · Cited by 686
Metadata
- Authors
- Lane, H.-Y., Chang, Y.-C., Liu, Y.-C., Chiu, C.-C., & Tsai, G. E.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2005-11-01
- Volume
- 62
- Issue
- 11
- Pages
- 1196
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2110678771
- Cited by
- 271
- References
- 39
- FWCI
- 9.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.